2012 Drugs that promote or inhibit coagulation

Therapeutic strategies

There is a delicate balance between thrombosis and hemorrhage.

Drugs that inhibit coagulation (which tip the balance toward hemorrhage/fibrinolysis) are used to treat acute coronary syndromes (ACS) esp. myocardial infarctions, stroke, pulmonary embolism, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT) --- all potentially life-threatening conditions. There are 3 treatment strategies: degrade fibrinogen/fibrin (thrombolytics), inhibit the clotting mechanism (anticoagulants) and prevent initial clot formation (anti-platelet drugs).  The most serious potential side effect of all of these agents is BLEEDING (especially hemorrhagic stroke).

Drugs that promote coagulation (which tip the balance toward clotting) either increase concentrations of natural clotting factors or are antagonists of thrombolytics. These drugs are used to treat bleeding disorders, such as hemophilia.
Critical fact icon


Email: Dr. Janet Fitzakerley | ©2012 University of Minnesota Medical School Duluth | Last modified: 31-may-12 7:25 PM